Navigation Links
Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update

SOUTH EASTON, Mass., March 12 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that total revenue for 2007 was $645,870 compared to $210,289 for 2006. Revenue from the sale of PCT products and services was $399,787 for the year as compared to $210,289 for the prior year. This increase in revenue from PCT products and services was primarily the result of the number of installations of the Company's PCT Sample Preparation Systems ("PCT Systems") - the total number of PCT Systems installed during 2007 was twenty, as compared to eight in 2006. Also contributing to this increase in revenue was an increase in the number of PULSE Tubes and ProteoSolve-LRS Kits sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded $246,083 of grant revenue during 2007. There was no grant revenue recognized during 2006.

As of December 31, 2007, the Company had cash and cash equivalents of approximately $5.4 million, as compared to approximately $5.3 million on December 31, 2006. Edward H. Myles, Senior Vice President of Finance and CFO commented: "During 2007, we effectively financed the continued development and initial commercialization of PCT with proceeds received from the liquidation of our investment in Panacos Pharmaceuticals common stock, the divestiture of Source Scientific LLC, and the sale of 126,750 shares of our common stock in our private placement completed in November 2007."

Mr. Myles continued: "Our installation of twenty PCT Systems represents a significant increase compared to the prior year. These installations came in the form of sales, leases, and rental agreements. Furthermore, included in our 2007 revenue was the sale of several of our recently launched Barocycler NEP2320 units, which have a price of approximately one half of the Barocycler NEP3229. Consistent with our strategy, we are working to drive our installed base of PCT Sample Preparation Systems so that we can continue to realize increases in our recurring revenue streams from PULSE Tubes, ProteoSolve-LRS Kits, and extended service contracts."

Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. said: "We are proud of the accomplishments of 2007 and believe that these accomplishments position us well for success in 2008. On the sales and marketing front, we have completed the hiring of seven experienced, US-based, Regional Sales Directors. Through the efforts of our marketing department, we have increased the number of leads in the US by over 2,000, and we expect that our new Regional Sales Directors will contact many of them during 2008. We also are ahead of schedule in building our international distribution network as we now have distribution agreements with three partners covering France, Switzerland, Belgium, Japan, and Korea."

Mr. Schumacher continued: "On the research and development side of the business, our accomplishments are numerous: in Engineering R&D, we drove the Barocycler NEP2320 from concept to prototype to product launch in less than a year, and in Applications R&D, we drove our ProteoSolve-LRS Kit from discovery to patent filing to scientific meeting presentation to product launch in less than eight months. In addition, in December 2007, we were awarded the prestigious Frost and Sullivan Innovation Research Award for the development of ProteoSolve-LRS."

Mr. Schumacher concluded: "We look to 2008 as the year that all of the ingredients for success may come together. We have revolutionary technology, a newly hired but experienced sales force, product in inventory, and a potential universe of approximately 390,000 scientists worldwide who might benefit from the advantages of the PCT Sample Preparation System. I am very proud of the progress that we've made in the three short years since we became Pressure BioSciences, I would like to compliment all of our employees for their hard work and dedication to date, and I would like to thank all of our shareholders for their past and continued support."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Financial Teleconference and Web-cast

As announced on March 6, 2008, the Company will host a teleconference at 4:30 pm EDST on Wednesday, March 12, 2008 to discuss its 2007 financial results and to provide a business update.

To attend this teleconference via web-cast, please go to the Company's website:

To attend this teleconference via telephone, please dial:

(800) 909-5202

Participant code: 4382794

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through April 4, 2008, and will be accessible through the Company's website. To access the replay, please dial (888) 203-1112 and enter code 4382794.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the Company's expectations for 2008, including the potential for additional installations of PCT Systems, increased revenues from such installations, the sale of PULSE Tubes, ProteoSolve-LRS Kits and extended service contracts, the ability to convert leads into sales, leases or rental of the PCT System, the ability to continue to develop an international distribution network, the number of scientists who might benefit from the PCT Sample Preparation System, the anticipated quality and benefits of the Company's products, and beliefs regarding the validation of the Company's business plan due to the Company's growing installed base of PCT Systems. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; the Company's financial results for the fiscal year ended December 31, 2007 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customers needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen cost increases; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company's new external sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; and the Company may be unable to develop new PCT-related products that are perceived by potential customers as having advantages over current technologies and techniques. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website

Consolidated Balance Sheets

December 31,

ASSETS 2007 2006


Cash and cash equivalents $5,424,486 $5,335,282

Accounts receivable 118,471 37,495

Inventories 172,548 19,658

Deposits 553,483 175,300

Prepaid income taxes 56,863 38,687

Income tax receivable 249,541 710,013

Prepaid expenses and other current assets 94,783 71,476

Investments in marketable securities - 2,060,875

Total current assets 6,670,175 8,448,786



Intangible assets, net 328,290 376,922

Assets of discontinued operation - 1,420,996

Total other assets 328,290 1,797,918

TOTAL ASSETS $7,256,262 $10,454,400



Accounts payable $152,729 $174,289

Accrued employee compensation 377,190 242,497

Accrued professional fees and other expenses 186,840 150,978

Income taxes payable 4,519 45,962

Deferred taxes - 669,520

Deferred revenue 15,075 4,099

Total current liabilities 736,353 1,287,345


Deferred revenue 6,767 9,126

Liabilities of discontinued operation - 1,042,493

Total long term liabilities 6,767 1,051,619

TOTAL LIABILITIES 743,120 2,338,964



Preferred stock; 1,000,000 shares authorized;

0 outstanding - -

Common stock, $.01 par value; 20,000,000

shares authorized; 2,192,175 and 2,065,425

shares issued and outstanding 21,922 20,654

Additional paid-in capital 6,284,616 5,347,641

Accumulated other comprehensive income - 1,384,876

Retained earnings 206,604 1,362,265

Total stockholders' equity 6,513,142 8,115,436


Consolidated Statements of Operations

For the Year Ended

December 31,

2007 2006


PCT Products, services, other $399,787 $210,289

Grant revenue 246,083 -

Total revenue 645,870 210,289


Cost of PCT products and services 209,050 165,233

Research and development 2,022,730 1,429,711

Selling and marketing 1,386,519 528,265

General and administrative 2,174,739 2,145,196

Total operating costs and

expenses 5,793,038 4,268,405

Operating loss from continuing

operations (5,147,168) (4,058,116)


Realized gain on securities available

for sale 2,028,720 517,938

Interest income 286,600 381,713

Total other income 2,315,320 899,651

Loss from continuing operations

before income taxes (2,831,848) (3,158,465)

Income tax benefit from

continuing operations 520,214 745,354

Loss from continuing operations (2,311,634) (2,413,111)


Gain on sale of net assets related

to discontinued operations (net of

income tax of $218,060) 1,155,973 -

Net loss $(1,155,661) $(2,413,111)

Loss per share from continuing

operations - basic and diluted $(1.11) $(1.01)

Income per share from discontinued

operations - basic and diluted 0.55 -

Net loss per share - basic and

diluted $(0.56) $(1.01)

Weighted average number of shares

used to calculate income (loss)

per share - basic and diluted 2,078,657 2,396,077

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.

(T) 508-230-1828

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Specific antagonism lowers blood pressure
3. Doctors Often Miss High Blood Pressure in Kids
4. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
5. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
6. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio
7. AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
8. Memory tasks require more coordinated brain blood flow for people with high blood pressure
9. Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids Licensed Foods and Beverages
10. High Blood Pressure & Stroke Attack was the Focus for the Third Stop of the 2007 Empowerment Tour for a Healthier Life
11. Daytime, Nighttime Blood Pressure Both Important
Post Your Comments:
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  Trovagene, Inc. (NASDAQ: TROV ... that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled ... Annual Piper Jaffray Healthcare Conference. th ... York Palace Hotel in New York ... EST. Mr. Schuh will be available for one-on-one meetings ...
(Date:11/25/2015)... Nov. 25, 2015 USP 800 applies ... preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician ... The chapter also covers all entities which store, ... hospitals, other healthcare institutions, patient treatment clinics, physicians, ... --> --> What is the ...
(Date:11/25/2015)... , November 25, 2015 Developmental, commercial, ... role in boosting the profitability of pharmaceutical products, ... commercial, and regulatory/legal strategies all play a ... says GBI Research . --> ... play a key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology: